{"id":"https://openalex.org/W2344595682","doi":"https://doi.org/10.1089/aid.2014.5054.abstract","title":"Development of a V1/V2-targeting Quaternary-specific Broadly Neutralizing Lineage","display_name":"Development of a V1/V2-targeting Quaternary-specific Broadly Neutralizing Lineage","publication_year":2014,"publication_date":"2014-10-01","ids":{"openalex":"https://openalex.org/W2344595682","doi":"https://doi.org/10.1089/aid.2014.5054.abstract","mag":"2344595682"},"language":"en","primary_location":{"id":"doi:10.1089/aid.2014.5054.abstract","doi":"https://doi.org/10.1089/aid.2014.5054.abstract","is_oa":false,"landing_page_url":"https://doi.org/10.1089/aid.2014.5054.abstract","pdf_url":null,"source":{"id":"https://openalex.org/S161282271","display_name":"AIDS Research and Human Retroviruses","issn_l":"0889-2229","issn":["0889-2229","1931-8405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS Research and Human Retroviruses","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080977404","display_name":"Elise Landais","orcid":"https://orcid.org/0000-0002-8183-5565","observed_orcids":["https://orcid.org/0000-0002-8183-5565"]},"institutions":[{"id":"https://openalex.org/I1310987316","display_name":"International AIDS Vaccine Initiative","ror":"https://ror.org/05ayv2203","country_code":"US","type":"funder","lineage":["https://openalex.org/I1310987316"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elise Landais","raw_affiliation_strings":["The International AIDS Vaccine Initiative, Neutralizing Antibody Center, La Jolla, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The International AIDS Vaccine Initiative, Neutralizing Antibody Center, La Jolla, CA, United States","institution_ids":["https://openalex.org/I1310987316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067720514","display_name":"Bryan S. Briney","orcid":"https://orcid.org/0000-0001-9535-2866","observed_orcids":["https://orcid.org/0000-0001-9535-2866"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan S. Briney","raw_affiliation_strings":["The Scripps Research Institute, Department of Immunology and Microbial Sciences, La Jolla, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology and Microbial Sciences, La Jolla, CA, United States","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029158313","display_name":"Sergei L. Kosakovsky-Pond","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sergei L. Kosakovsky-Pond","raw_affiliation_strings":["University of California San Diego, Department of Medicine, La Jolla, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California San Diego, Department of Medicine, La Jolla, CA, United States","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037466669","display_name":"Daniel T. MacLeod","orcid":"https://orcid.org/0009-0003-0871-0357","observed_orcids":["https://orcid.org/0009-0003-0871-0357"]},"institutions":[{"id":"https://openalex.org/I1310987316","display_name":"International AIDS Vaccine Initiative","ror":"https://ror.org/05ayv2203","country_code":"US","type":"funder","lineage":["https://openalex.org/I1310987316"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel T. MacLeod","raw_affiliation_strings":["The International AIDS Vaccine Initiative, Neutralizing Antibody Center, La Jolla, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The International AIDS Vaccine Initiative, Neutralizing Antibody Center, La Jolla, CA, United States","institution_ids":["https://openalex.org/I1310987316"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109346556","display_name":"Yolanda Lie","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yolanda Lie","raw_affiliation_strings":["Monogram Biosciences Inc, San Francisco, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Monogram Biosciences Inc, San Francisco, CA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967801","display_name":"Paul A. Algate","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111789","display_name":"Theraclone Sciences (United States)","ror":"https://ror.org/026vbm280","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111789"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Algate","raw_affiliation_strings":["Theraclone Sciences Inc., Seattle, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theraclone Sciences Inc., Seattle, WA, United States","institution_ids":["https://openalex.org/I4210111789"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058546353","display_name":"Dennis R. Burton","orcid":"https://orcid.org/0000-0001-6711-9864","observed_orcids":["https://orcid.org/0000-0001-6711-9864"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis R. Burton","raw_affiliation_strings":["The Scripps Research Institute, Department of Immunology and Microbial Sciences, La Jolla, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology and Microbial Sciences, La Jolla, CA, United States","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034553895","display_name":"Terri Wrin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Terri Wrin","raw_affiliation_strings":["Monogram Biosciences Inc, San Francisco, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Monogram Biosciences Inc, San Francisco, CA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068629370","display_name":"Po-Ying Chan-Hui","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111789","display_name":"Theraclone Sciences (United States)","ror":"https://ror.org/026vbm280","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111789"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Po-Ying Chan-Hui","raw_affiliation_strings":["Theraclone Sciences Inc., Seattle, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theraclone Sciences Inc., Seattle, WA, United States","institution_ids":["https://openalex.org/I4210111789"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024254197","display_name":"Pascal Poignard","orcid":"https://orcid.org/0000-0002-0021-7192","observed_orcids":["https://orcid.org/0000-0002-0021-7192"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]},{"id":"https://openalex.org/I1310987316","display_name":"International AIDS Vaccine Initiative","ror":"https://ror.org/05ayv2203","country_code":"US","type":"funder","lineage":["https://openalex.org/I1310987316"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pascal Poignard","raw_affiliation_strings":["The International AIDS Vaccine Initiative, Neutralizing Antibody Center, La Jolla, CA, United States","The Scripps Research Institute, Department of Immunology and Microbial Sciences, La Jolla, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The International AIDS Vaccine Initiative, Neutralizing Antibody Center, La Jolla, CA, United States","institution_ids":["https://openalex.org/I1310987316"]},{"raw_affiliation_string":"The Scripps Research Institute, Department of Immunology and Microbial Sciences, La Jolla, CA, United States","institution_ids":["https://openalex.org/I123431417"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.21275729,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"S1","first_page":"A34","last_page":"A35"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hiv-1-vaccine","display_name":"HIV-1 vaccine","score":0.8019999861717224},{"id":"https://openalex.org/keywords/broadly-neutralizing-antibodies","display_name":"broadly neutralizing antibodies","score":0.9520000219345093},{"id":"https://openalex.org/keywords/hiv-1-envelope-glycoprotein","display_name":"HIV-1 envelope glycoprotein","score":0.5170000195503235},{"id":"https://openalex.org/keywords/aidsvax-b-e","display_name":"AIDSVAX B/E","score":0.9570000171661377},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.7459999918937683},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.9900000095367432},{"id":"https://openalex.org/keywords/rv144","display_name":"RV144","score":0.7639999985694885}],"concepts":[{"id":"https://openalex.org/C2776817793","wikidata":"https://www.wikidata.org/wiki/Q6553369","display_name":"Lineage (genetic)","level":3,"score":0.6354789733886719},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5396684408187866},{"id":"https://openalex.org/C160464908","wikidata":"https://www.wikidata.org/wiki/Q26185","display_name":"Quaternary","level":2,"score":0.5345605611801147},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.49634629487991333},{"id":"https://openalex.org/C78458016","wikidata":"https://www.wikidata.org/wiki/Q840400","display_name":"Evolutionary biology","level":1,"score":0.4538908004760742},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.3371455669403076},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.3277036249637604},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.1691945195198059},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.1673758625984192}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1089/aid.2014.5054.abstract","doi":"https://doi.org/10.1089/aid.2014.5054.abstract","is_oa":false,"landing_page_url":"https://doi.org/10.1089/aid.2014.5054.abstract","pdf_url":null,"source":{"id":"https://openalex.org/S161282271","display_name":"AIDS Research and Human Retroviruses","issn_l":"0889-2229","issn":["0889-2229","1931-8405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS Research and Human Retroviruses","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2113226921","https://openalex.org/W2973305373","https://openalex.org/W2974407582","https://openalex.org/W4410379745","https://openalex.org/W2065353103","https://openalex.org/W1996287505","https://openalex.org/W2806024756","https://openalex.org/W2411099468","https://openalex.org/W4283589001","https://openalex.org/W2320824321"],"abstract_inverted_index":{"Background:":[0],"Following":[1],"the":[2,22,128,138,290],"RV144":[3,296],"trial":[4],"demonstration":[5],"of":[6,148,191,256,279],"31%":[7],"vaccine":[8,51,292],"efficacy":[9],"in":[10,14,25,42,53,213,237,285,295,307],"preventing":[11],"HIV":[12,50,91,116],"infection":[13],"Thailand,":[15],"HVTN":[16],"097":[17],"was":[18,40,57,100,201],"designed":[19],"to":[20,28,37,125,157,208,245,301],"evaluate":[21],"same":[23,291],"regimen":[24,52,293],"South":[26,54,286],"Africans":[27,287],"ascertain":[29],"whether":[30],"their":[31],"immune":[32,71],"response":[33,144,189,224,317],"profiles":[34],"were":[35,133,177,243,262,297],"similar":[36,47,207,244],"Thais.This":[38],"study":[39,56],"conducted":[41],"preparation":[43],"for":[44,271],"evaluating":[45],"a":[46],"clade":[48,85],"C":[49],"Africa.Our":[55],"critical":[58],"as":[59],"previous":[60],"studies":[61],"have":[62],"demonstrated":[63],"that":[64],"age,":[65,180],"gender":[66,181],"and":[67,84,94,96,107,121,146,160,164,171,182,265,277],"BMI":[68,254,272,310],"impact":[69],"vaccine-induced":[70],"responses.Methods:":[72],"ALVAC-HIV":[73],"(vCP1521)":[74],"expressing":[75,152,197],"HIV-1":[76,158],"Env":[77],"(clade":[78,98],"E,":[79],"gp120":[80,117,159],"from":[81,89],"strain":[82,90],"92TH023":[83],"B":[86,119],"TM":[87],"gp41":[88],"Lai":[92],",":[93],"Gag":[95],"protease":[97],"B)":[99],"administered":[101],"at":[102,127,298],"baseline":[103],"then":[104],"1,":[105],"3":[106],"6":[108],"months":[109],"later":[110],"with":[111],"AIDSVAX":[112],"\u00d2":[113],"B/E,":[114],"bivalent":[115],"subtypes":[118],"(MN)":[120],"E":[122],"(A244)":[123],"adsorbed":[124],"alum":[126],"last":[129,139],"2":[130,135],"vaccinations.Immune":[131],"responses":[132,176,212],"measured":[134],"weeks":[136],"after":[137],"immunization.Intracellular":[140],"Cytokine":[141],"Staining":[142],"identified":[143],"rates":[145,190,225,236,251,276],"frequencies":[147],"HIV-specific":[149],"T":[150,195,283],"cells":[151,196,284],"IFN-c":[153,198],"and/or":[154,199],"IL-2.Binding":[155],"antibodies":[156],"V1V2,":[161],"IgG":[162],"subclass,":[163],"antibody":[165],"functions":[166],"(ADCC,":[167],"avidity":[168],"index,":[169],"nAb,":[170],"virion":[172],"capture)":[173],"are":[174],"ongoing.Immune":[175],"stratified":[178,252],"by":[179,253,289],"BMI.Results:":[183],"In":[184],"68":[185],"participants,":[186],"overall":[187],"peak":[188],"Envspecific":[192],"CD4":[193,281,314],"+":[194,282,315],"IL-2":[200],"70.6%":[202],"(95%":[203],"CI":[204],"58.9%,":[205],"80.1%),":[206],"or":[209,302,309],"greater":[210],"than":[211,227,304],"RV144.Although":[214],"not":[215,312],"significant,":[216],"participants":[217],"<":[218,257,269],"25":[219],"years":[220],"old":[221],"had":[222],"higher":[223],"observed":[226],"those":[228,305],"\u2021":[229,273],"26":[230],"(76.0%":[231],"vs.":[232],"55.6%,p":[233],"=":[234],"0.108).Response":[235],"females":[238],"(75%;":[239],"95%CI":[240,248],"56.6%,":[241],"87.3%)":[242],"males":[246],"(67.5%;":[247],"52.0%,":[249],"79.9%).Response":[250],"categories":[255],"25,":[258],"25-30,":[259],">":[260],"30":[261],"63.6%,":[263],"82.4%":[264],"85.7%,":[266],"respectively":[267],"(p":[268],"0.1":[270],"25).Conclusions:":[274],"Response":[275],"magnitudes":[278],"Env-specific":[280],"induced":[288,306],"used":[294],"least":[299],"comparable":[300],"better":[303],"RV144.Age/gender":[308],"did":[311],"affect":[313],"T-cell":[316],"rates.":[318]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2016-06-24T00:00:00"}